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Abstract
Background: We compared the diagnostic accuracy and reproducibility of commercially available NS1-based
dengue tests and explored factors influencing their sensitivities.
Methods: Paired analysis of 310 samples previously characterized as positive (n = 218) and negative (n = 92) for
viral isolation and/or RT-PCR and/or IgM seroconversion. Masked samples were tested by two observers with
Platelia™ Dengue NS1 Ag, second generation Pan-E™ Dengue Early ELISA, SD Dengue NS1 Ag ELISA, Dengue NS1
Ag STRIP™, and SD BIOLINE™ Dengue Duo (NS1/IgM/IgG).
Results: SD BIOLINE™ NS1/IgM/IgG had the highest sensitivity (80.7% 95%CI 75-85.7) with likelihood ratios of 7.4
(95%CI 4.1-13.8) and 0.21 (95%CI 0.16-0.28). The ELISA-format tests showed comparable sensitivities; all below 75%.
STRIP™ and SD NS1 had even lower sensitivities (<65%). The sensitivities significantly decreased in samples taken
after 3 days of fever onset, in secondary infections, viral serotypes 2 and 4, and severe dengue. Adding IgM or IgG
to SD NS1 increased its sensitivity in all these situations.
Conclusions: The simultaneous detection of NS1/IgM/IgG would be potentially useful for dengue diagnosis in
both endemic and non endemic areas. A negative result does not rule out dengue. Further studies are required to
assess the performance and impact of early laboratory diagnosis of dengue in the routine clinical setting.
Background
Dengue is a vector borne disease rapidly spreading in
urban areas in tropical and subtropical countries. It is
estimated that at least 10% of dengue fever cases evolve
to severe and eventually lethal forms of the disease. The
clinical and laboratory findings in dengue are very simi-
lar to those of other febrile diseases that are prevalent
in the same geographical regions [1]. Therefore, a den-
gue diagnostic test is required for adequate case man-
agement and to reduce misclassification in the dengue
surveillance system. However, dengue diagnosis in the
first days of fever is yet problematic.
There are three main laboratory methods to diagnose
dengue infection: viral isolation in culture, detection of
viral RNA, and specific IgM/IgG antibodies in paired
sera. The gold standard is usually a combination of
these methods [1,2]. Viral isolation is costly, the results
are usually available after 6 to 10 days and it is only
obtainable in laboratories with the appropriate infra-
structure for cell culture or mosquito colonies. The RT-
PCR and other PCR-based techniques give results within
24 hours but they are also costly and they are not avail-
able for most clinicians. On the contrary, there are com-
mercially available immunochromatographic and ELISA
tests for the detection of IgM/IgG antibodies which give
results within minutes or few hours. However, the
detection of antibodies in a dengue infected person is
only possible after 4-5 days of disease onset. Moreover,
a single positive IgM or IgG result suggests recent infec-
tion but paired sera samples showing seroconversion or
a fourfold titer increase are required to confirm diagno-
sis [1].
Recently, several dengue diagnostic tests based on the
detection of NS1 (Non-structural Protein 1) have
become commercially available. NS1 is a highly
* Correspondence: lyda1oso@gmail.com
1Grupo de Epidemiologia y Salud Poblacional (GESP) Escuela de Salud
Publica, Facultad de Salud, Universidad del Valle. Cali, Colombia Calle 4b
36-140, Cali-Colombia
Full list of author information is available at the end of the article
Osorio et al. Virology Journal 2010, 7:361
http://www.virologyj.com/content/7/1/361
© 2010 Osorio et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.conserved glycoprotein of flaviviruses including Dengue,
Japanese encephalitis, Yellow fever and tick-borne ence-
phalitis virus [3]. The specificity of the NS1-based Den-
gue tests is reported to be between 86.1% and 100% and
false positives are considered rare [4,5]. Higher variabil-
ity (between 37% and 98.9%) has been reported in the
sensitivity of these tests (Table 1) [6-24]. This variability
could be partly explained by the fact that sensitivity has
been found to decrease with time after fever onset and
in secondary infections [12,18,21]. The addition of IgM
and IgG specific antibodies detection to NS1-based tests
in a single kit has been suggested [25] may improve the
assessment of dengue infection status and one such test
(SD BIOLINE™ Dengue Duo) has become commercially
available. With all these options in the market, it is
necessary to identify which of the current NS1-based
diagnostic tests would be potentially more useful in the
clinical setting. We sought to compare the performance
of the current commercially available NS1-based assays
for the early diagnosis (within 7 days since fever onset)
of dengue infections. The objectives of this study were:
1) To identify differences in sensitivity, specificity, and
likelihood ratios between all the diagnostic assays, 2) To
describe the effect of duration of symptoms, type of
infection, viral serotype, and severity of the disease on
the sensitivity of the tests, and 3) to determine the
reproducibility of each diagnostic test.
Methods
Type of study and sample size calculation
The study was a cross sectional case-reference design to
assess diagnostic tests [26]. A paired analysis of samples
from febrile subjects with and without dengue was done
using viral isolation, RT-PCR or IgM seroconversion as
gold standard. Sample size for dengue (n = 210) and
non-dengue (n = 100) was estimated based on an
expected 90% sensitivity and 100% specificity for the
Platelia™ test versus 80% sensitivity and 90% specificity
for the other assays. The Conner method for the paired
McNemar test was used for sample size calculation with
a5 %a l f aa n d2 0 %b e t ae r r o r s[ 2 7 ] .H a l fd e n g u ea n dn o
dengue samples were used to assess reproducibility.
Clinical samples
Stored serum (229, 73.9%) or plasma (81, 26.1%) sam-
ples from febrile subjects with clinically-suspected den-
gue infection who took part in studies carried out by
Universidad del Valle and Universidad Industrial de
Santander in Colombia between 2004 and 2008 were
selected randomly. The following criteria were consid-
ered: 1) dengue status known as a result of one or more
of the following: viral isolation, RT-PCR or IgM sero-
conversion, 2) sample taken between day 0 and 7 of
onset of fever, and 3) a minimum of 1 mL volume avail-
able. Day 0 was defined as the same day of fever onset.
To avoid the spectrum bias, samples representing sub-
jects who had been previously classified as dengue fever
and hemorrhagic dengue were included and further clas-
sified as non-severe and severe dengue, respectively [1].
Gold standard tests (viral culture, nested RT-PCR or
paired IgM) had been done during the previous studies
at the virology laboratory of Universidad del Valle.
Briefly, for viral isolation sera samples had been cultured
in the mosquito cell line clone C6/36 HT and incubated
at 33°C for 10 to 14 days. Viruses were detected and
identified by immunofluoresce with serotype specific
monoclonal antibodies 15F3 (DENV1), 3H5 (DENV2),
5 D 4( D E N V 3 )a n d1 H 1 0( D E N V 4 )( C h e m i c o nI n t e r n a -
tional, Inc. Temecula, California) and fluorescein iso-
thiocyanate-conjugated goat anti-mouse antibody [28].
For RT-PCR, viral RNA had been extracted with trizol
Table 1 Reported sensitivity and specificity of
commercially available NS1-based dengue diagnostic
tests
Test Sensitivity %
(95%IC)
Specificity %
(95%CI)
place
STRIP™ 61.6 (55.2-67.8) 100 (93.8-100) Vietnam [6]
PanE™ 49.4 (38.5-60.4) 100 (92.1-100) India [7]
STRIP™ 78.9 (70-86.1) 99 (94.6-99.9) Singapore [8]
PanE™ 67 (57.3-75.7) 100 (96.4-100) Singapore [8]
Platelia™ 81.7 (73.1-88.4) 100 (96.4-100) Singapore [8]
STRIP™ 89.6 (84.7-93.2) 99.1 (96.9-99.9) Brazil [9]
PanE™ 72.3 (65.8-78.1) 100 (98.4-100) Brazil [9]
Platelia™ 83.6 (78.1-88.2) 98.7 (96.2-99.7) Brazil [9]
Platelia™ 67.3 (57.1-76.4) - Finland [10]
Platelia™ 37 99.5 Vietnam [5]
Platelia™ 73.6 (63.7-81.6 - Australia [11]
PanE™ 63.7 (53.5-72). - Australia [11]
Platelia™ 83.2 (75.5-89.3) 100 (86.7-100.0) Vietnam [12]
Platelia™ 71.3 (61-80) 86.1 (70.9-94.4) Venezuela [13]
Pan E™ 60.9 (50.4-70.5) 94.4 (80.9-99.4) Venezuela [13]
STRIP™ 67.8 (57.4-76.7) 94.4 (80.9-99.4) Venezuela [13]
STRIP™ 90.4 (86.6-94.4) 99.5 (97.4-99.9) Malaysia [14]
STRIP™ 98.9 (96.8-100) 90.6 (85.6-95.7) Thailand [15]
STRIP™ 77.3 (0.54-0.92) 100 Taiwan [16]
Pan E™ 83.3 (65.2-94.3) - China [17]
Platelia™ 63.2 (55.7-70.0) 98.4 (91.7-99.7) Thailand [18]
Platelia™ 83.2 (77.5-87.7) 100 (92.1-100) Puerto Rico [19]
PanE™ 64.9 (58.2-71.1) 97.8 (88.4-99.6) Puerto Rico [19]
STRIP™ 77.6 (72.1-82.4) 100 (92.6-100) French Guiana [20]
Platelia™ 82.4 (77.3-86.7) 100 (92.6-100) French Guiana [20]
Pan E™ 55.1 (49.0-61.2) 97.9 (88.9-99.9) French Guiana [20]
Platelia™ 92.3 (64-99.8) 100 Thailand [21]
PanE™ 63 (53-73) 100 Laos [22]
Platelia™ 93.4 (89.2-96.3) 100 (98.9-100) Singapore [23]
Platelia™ 88.7 (94-92.4) 100 (98.9-100) French Guiana [24]
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Page 2 of 10(Gibco-BRL, Gaithersburg, MD) and cDNA obtained
with the reverse transcriptase of the Avian myeloblasto-
sis virus (Promega, Madison, WI) and a dengue univer-
sal antisense primer targeting the C/prM region of the
genome. cDNA amplification was performed with a
nested PCR using the same universal dengue primers in
a first round of amplification and viral serotype specific
primers in a second round of PCR [29]. Finally, IgM
MAC-ELISA in paired samples had been done using
affinity-purified goat anti-human IgM as a capture anti-
body (KPL; Gaitersburg, Maryland 1 μg/ml), followed by
addition of 1:40 dilution of serum samples duplicates.
Assay antigen was home-made and consisted of a mix-
ture of 4 HA U (hemoagglutinating units) each of the
four dengue serotypes obtained by i.c. inoculation of
suckling mice and antigen extraction by a sucrose/acet-
one gradient. Detection was performed using 1:10,000
dilution of a peroxidase-conjugated dengue-complex
specific monoclonal antibody MAB 6B6C-1 (kindly pro-
vided by CDC, San Juan de Puerto Rico) and substrate
p-nitrophenyl-phosphate [30,31]. Positivity was defined
as having an assay absorbance of ≥2.0 (405 nm) after
subtracting the background value (negative sample).
Because up to 30% of secondary dengue infections do
not have detectable IgM [32], and most non-dengue
samples had been analyzed only by paired IgM, samples
classified as non-dengue were further analyzed using an
algorithm of RT-PCR plus IgG and IH. All non-dengue
samples (except for four samples with insufficient
volume left) were processed with RT-PCR as described
elsewhere [29]. RT-PCR positives were considered as
dengue. To discard secondary infections which do not
increased IgM, all RT-PCR negative non-dengue sam-
ples underwent IgG detection in acute sera using Den-
gue Duo (IgM/IgG) Cassette (Inverness - Brisbane,
Australia). Non-dengue samples with negative IgG were
considered as true negatives. Those samples with
positive IgG were processed with haemagglutination-
inhibition test (HI) and considered as true negatives if
not increased (>2560) titers were detected in convales-
cent sera (Figure 1). HI was done at the virology labora-
tory of Universidad del Valle using goose red blood cells
and sucrose/acetone extracted antigens obtained in
suckling mice brains following Kuno et al. 1991 [33].
This study was approved by the Universidad del Valle
Ethics Review Board.
Diagnostic tests and procedures
All 5 diagnostic NS1-based tests commercially available
a tt h et i m eo ft h es t u d yw e r ea n a l y z e d .T h e s ei n c l u d e d :
Platelia™ Dengue NS1 Ag Test (Bio-Rad Laboratories -
Marnes La Coquette, France), second generation Pan-E™
Dengue Early ELISA (Inverness - Brisbane, Australia),
Dengue NS1 Ag ELISA (Standard diagnostic Inc. -
Kyonggi-do - South Korea), Dengue NS1 Ag STRIP™
(Bio-Rad), and SD BIOLINE™ Dengue Duo (Standard
diagnostic Inc.). The characteristics of the tests are sum-
marized in table 2. The Platelia™ Dengue NS1 Ag Test
and Dengue NS1 Ag STRIP™ were purchased from the
local distributor while the rest were kindly donated by
the manufacturers. All tests were run following the cor-
responding manufacturer’s instructions. Dengue NS1 Ag
STRIP™ was read at 15 min and 30 min. Three separate
results were obtained from SD BIOLINE™ Dengue Duo
test based on the results of NS1 only (dengue if NS1
was positive and non-dengue if NS1 was negative,
regardless of IgM/IgG results), NS1/IgM combined
(dengue if one of NS1 or IgM was positive and non-
dengue if both were negative, regardless of IgG results),
and NS1/IgM/IgG combined (dengue if at least one of
NS1, IgM or IgG was positive and non-dengue if all
three were negative). Batches of samples were analyzed
by all the NS1-based diagnostic tests on the same day
and by the same persons who were two experienced lab
scientists. Both observers were blind to the samples den-
gue status and each other results. Results of the ELISA-
based format tests given as “equivocal” were repeated
once. Persistent equivocal results were excluded from
t h ea n a l y s i s .T h o s er e s u l t so ft h ei m m u n o c h r o m a t o g r a -
phy-based format tests given as “weak” were considered
as positive results.
Statistical analysis
Data were double entered and validated using Epinfo
(Centers for Disease Control and Prevention, USA,
2000). Stata 10 (Stata Corporation, 2003) was used
for statistical analyses. First observer results were
used to obtain sensitivity, specificity, negative (NPV)
and positive (PPV) predictive values, positive and
negative likelihood ratios (LR) with their correspond-
ing 95% confidence intervals. Cochrane Q was used
to compare overall performance of ELISA tests and
of immunocromatographic tests. McNemar Chi
squared test or the equivalent exact test was used to
compare the diagnostic accuracy among each possible
pair of assays. The method proposed by Roldan-
Nofuentes and Del Castillo (2007) was used to iden-
tify significant statistical differences in the LR of all
tests [34] and carried out in Mathematica 7 (Wolfram
Research Inc., 2010). Sensitivities with their corresponding
95% confidence intervals were also calculated by stratum
of duration of symptoms (≤3a n d4 - 7d a y s ) ,p r i m a r y /
secondary infection (defined as absence/presence of speci-
fic IgG in acute sera based on the results of the SD Bio-
line™ Dengue Duo), severe and non severe infection, and
viral serotype. Reproducibility of the tests (inter-observer
agreement) was assessed using Kappa indexes (k). We
interpreted k results as follows: values of less than 0, poor;
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erate agreement; 0.6 to 0.8, substantial agreement; and
values of 0.8 to 1.0 almost perfect agreement [35]. Funds
allowed us to purchase a limited number of Dengue NS1
Ag STRIP™ and hence results were available for 147 sam-
ples (104 dengue and 43 non-dengue). It was not possible
to assess reproducibility of this test. A P value <5% was
considered as statistically significant.
Figure 1 Study sample selection and laboratory analyses.
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A total of 310 samples were included in the study from
which 210 were classified as dengue and 100 as non-
dengue. Eight samples initially classified as non-dengue
based on IgM negative results in paired serum samples
were RT-PCR-positive and hence were reclassified as
dengue. Therefore, for the final analysis there were 218
dengue and 92 non-dengue cases. Samples represented
all age groups and had a median of 3 days of fever
onset. Nine samples analyzed by Platelia™ and 2 by Pan
E™ gave equivocal results and were run twice. The sec-
ond time, both Pan E™ and 2 Platelia™ results were nega-
tive while the other 7 (1 non-dengue and 6 dengue)
remained equivocal and were excluded from the final
analyses (Figure 1). Sixty four (29.4%) dengue samples
were positive for IgG in the SD Bioline™ Dengue Duo
and were considered as secondary infections. Secondary
infections had a median of 4 (range 2-7) days of fever
onset and dengue serotype was identified in 42 of these
cases: 13 DENV1, 17 DENV2, 7 DENV3, and 5 DENV4.
Sensitivity and specificity of tests ranged from 51% to
80.7% and from 89.1% to 96.7%, respectively (Table 3).
SD BIOLINE™ NS1/IgM/IgG had the highest sensitivity
(80.7% 95%CI 75-85.7) followed by SD BIOLINE™ NS1/
IgM (78.4% 95%CI 72.4-83.7) and Pan E™ (71.1% 95%CI
64.6-77). There were not statistically significant differ-
ences in the diagnostic accuracy of the three ELISA-
based assays (p = 0.9). For the immunocromatographic
tests, STRIP™ read at 30 min had a higher diagnostic
accuracy (71.4%, 105/147) than STRIP™ read at 15 min
(68.7%, 101/147) but this difference was not statistically
significant (p = 0.1). The diagnostic accuracy did not
differ among SD BIOLINE™ NS1/IgM (82.2%, 255/310)
and SD BIOLINE™ NS1/IgM/IgG 83.2, 258/310 (p =
0.4). However, their diagnostic accuracy was higher than
all the other immunochromatographic and ELISA tests
(p<0.05 for all pair wise comparisons).
In line with the relatively high specificity found, the
PPVs were above 90% for all tests. In contrast, the high-
est NPV was 66.1% (95%CI 57.1-74.4). LR+ varied
between 6.5 and 15.6 while LR-varied between 0.2 and
0.5 (Table 3). Statistically significant differences in LR
were found between all tests pair wise comparisons
except Platelia™ Vs. PanE™,P l a t e l i a ™ Vs. STRIP™,a n d
ELISA SD™ Vs. STRIP™. The sensitivity of NS1-based
diagnostic tests significantly decreased in those samples
taken after 3 days of fever onset, in secondary infections,
viral serotypes 2 and 4, and severe dengue. Adding IgM
or IgG to SD BIOLINE™ NS1 increased its sensitivity in
all these situations (Figure 2). The positive effect of add-
ing IgM to NS1 in the sensitivity of the test was more
noticeable in samples with detectable IgG regardless of
the days of fever onset (Table 4).
The inter-observer agreement was almost perfect for
Pan E™ (k = 0.94 CI95% 0.88-0.99), ELISA SD™ (k = 0.89
CI95% 0.82-0.96), SD BIOLINE™ NS1 (k = 0.90 CI95%
0.83-0.98), and the IgM cassette of SD BIOLINE™ (k =
0.85 CI95% 0.76-0.94) while substantial agreement was
observed with Platelia™ (k = 0.75 CI95% 0.60-0.89)
and the IgG cassette of SD BIOLINE™ (k = 0.7 CI95%
0.56-0.84).
Discussion
I nt h ep r e s e n ts t u d yw ec o m p a r e ds i m u l t a n e o u s l yt h e
performance of 5 commercially available tests for the
early (within 7 days of fever onset) diagnosis of dengue.
Table 2 Characteristics of the evaluated NS1-based dengue diagnostic tests
Test name Platelia™
Dengue
NS1 Ag Test
Pan-E™
Dengue
Early
SD Dengue
NS1 Ag
Dengue NS1
Ag STRIP™
SD BIOLINE™
Dengue Duo test
Company Bio-Rad Inverness Standard
diagnostic Inc
Bio-Rad Standard diagnostic Inc
Country France Australia South Korea France South Korea
Method of detection ELISA ELISA ELISA Immunochromatography Immunochromatography
Number of tests per pack 96 96 96 25 1 (of each NS1, IgM and IgG)
Volume of sample
required
50 μL 60-75 μL5 0 μL5 0 μL8 5 μL (75 for NS1 plus 10 for
IgM/IgG)
Time to result 2.5 h 2.5 h 2.5 h 15-30 min 20 min
Additional equipment
required?
Yes Yes Yes No No
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96.7%) of the NS1-based tests found in the present
study fell within the range described elsewhere
(Table 1). In previous comparative studies the sensitivity
of Platelia™ (71.3%-87.4%) was consistently higher than
STRIP™ (67.8%-82.4%) and, in turn, the sensitivity of
STRIP™ was higher than Pan E™ (60.4%-64.9%). By con-
trast, we did not find differences in the diagnostic accu-
racy of the ELISA-format diagnostic tests (Platelia™,P a n
E™ and ELISA SD™). In the present study, Pan E™ sensi-
tivity was higher than in the previous reports probably
because we used Pan E™ second generation, which uses
less diluted controls and samples (1:2 instead 1:10) than
the previous version [36]. Despite ELISA-format tests
showing comparable sensitivities, they were all below
75%. The immunocromatographic-format tests that
detect only NS1 had even lower sensitivities. This
means that a negative result on any of these tests does
not rule out dengue. The immunocromatographic SD
Bioline™ that detects simultaneously NS1 and specific
IgM/IgG showed the highest sensitivity (80.7% CI95%
75-85.7) which was comparable to the 83.7% (95%CI
78.4 - 88.1) reported in Vietnam [6]. Similarly, the addi-
tion of IgM has shown to improve the sensitivity of NS1
ELISA-format tests from 63.2% to 79% on admission
samples without significantly decreasing specificity [22].
Although we did not find statistically significant differ-
ences in the addition of IgM only or both antibodies to
NS1, the use of IgG could have clinical significance
when correlated with disease evolution and the days of
fever onset. In any case, a positive result for IgM or IgG
in a single sample does not confirm dengue, therefore;
the impact of false positives in the routine clinical set-
ting should be assessed.
Predictive values depend on the prevalence of the dis-
ease but their trend here showed that all tests were
comparable. For potential clinical use, LR measures of
diagnostic tests performance are more useful than pre-
dictive values. They tell how the test results modified
the pretest probability of disease independent of its pre-
valence. LR values above 10 and below 0.1 are consid-
ered conclusive to rule in or rule out diagnoses,
r e s p e c t i v e l yw h i l ev a l u e so f5t o1 0a n d0 . 1t o0 . 2a r e
frequently helpful to take clinical decisions [37]. In a
scenario where a clinician’s interest is to confirm dengue
diagnosis any of the tests is likely to be useful but they
should be aware that a negative test does not rule out
dengue. Hence, further diagnostics such as paired IgM
or IgG to assess seroconversion or titer increase would
need to be done. On the contrary, if ruling out dengue
Table 3 Measures of performance of commercially available NS1 detection-based dengue diagnostic assays
Assay Dengue
samples
Non-dengue
samples
Positive
tests
Negative
tests
Sensitivity %
(95% CI)
Specificity %
(95% CI)
PPV %
(95% CI)
NPV %
(95% CI)
LR+
(95% CI)
LR-
(95% CI)
Platelia™ 212 91 150 84 70.8 92.3 95.5 57.5 9.2 0.31
(64.1-76.8) (84.8-96.9) (91-98.2) (49.1-65.7) (4.5-18.8) (0.25-0.39)
PanE™ 218 92 155 82 71.1 89.1 94 56.6 6.54 0.32
(64.6-77) (80.9-94.7) (89.1-97.1) (48.1-64.8) (3.62-11.8) (0.26-0.4)
ELISA SD™ 218 92 150 87 68.8 94.6 96.8 56.1 12.7 0.33
(62.2-75) (87.8-98.2) (92.6-99) (48-64.1) (5.37-29.8) (0.27-0.4)
SD Bioline™ 218 92 111 89 51 96.7 97.4 45.4 15.6 0.5
NS1 only (44.1-57.7) (90.8-99.3) (92.5-99.5) (38.3-52.7) (5.1-48) (0.44-0.58)
SD Bioline™ 218 92 171 84 78.4 91.3 95.5 64.1 9.02 0.23
NS1/IgM (72.4-83.7) (83.6-96.2) (91.4-98.1) (55.3-72.3) (4.64-17.6) (0.18-0.3)
SD Bioline™ 218 92 176 82 80.7 89.1 94.6 66.1 7.43 0.21
NS1/IgM/IgG (75-85.7) (81-94.7) (90.3-97.4) (57.1-74.4) (4.12-13.8) (0.16-0.28)
STRIP™ 104 43 60 41 57.7 95.3 96.8 48.2 12.4 0.44
15 min (47.6-67.3) (84.2-99.4) (88.8-99.6) (37.3-59.3) (3.17-48.5) (0.35-0.56)
STRIP™ 104 43 64 41 61.5 93.3 97 50.6 13.2 0.4
30 min (51.5-70.9) (84.2-99.4) (89.5-99.6) (39.3-62) (3.4-51.6) (0.31-0.5)
PPV = Positive Predictive Value, NPV = Negative Predictive Value, LR = Likelihood Ratio
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NS1/IgM/IgG would provide more useful information
than any of the other tests (LR = 0.21). However, it
ought not to be considered as a screening test. Further
studies with larger sample size would be required to
give more precise estimates of LR.
The simultaneous detection of NS1 and specific IgM/
IgG appeared to overcome the limitations of using only
Figure 2 Sensitivity (with corresponding 95%CI) of NS1-based dengue diagnostic tests according to days of fever onset (A), type of
infection (B), viral serotype (C), and (D) severity of disease.
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subjects who seek treatment after 3 days of disease
onset and on severe cases. Our results confirmed that
sensitivity of NS1-based tests decreased in secondary
infections and with time of fever onset [12,18,20,21,23].
In contrast to Chaiyaratana et al. (2009), we also found
a decreased sensitivity of all assays in severe cases
because, in our study, these were more likely to be sec-
ondary infections (OR = 3,01 95%CI 1.57-5.78) and pre-
sented after 4 days of fever (OR = 4.31 95%CI 2.04-9.1)
than non-severe infections [15]. The addition of IgM/
IgG appeared to increase the sensitivity of NS1 Bioline™
in all 4 dengue serotypes. Nevertheless, the sensitivities
of all tests were consistently lower in DENV2 and
DENV4 infections as was also observed in Venezuela
[ 1 3 ]a n dP u e r t oR i c o[ 1 9 ] .T h e frequency of secondary
infections and time since disease onset could only partly
explain these differences because, in our study, only
DENV4 tended to be associated with the presence of
IgG in acute sera and samples taken after 4 days of
fever (data not shown). Viraemia levels were found to
be significantly higher in DENV1 than DENV2 and
DENV4 infected subjects in Vietnam [38]. Therefore,
differences in viral loads could be an alternative expla-
nation for the observed effect of serotype in NS1-based
tests sensitivity. In spite of this, no differences in sensi-
tivity of Platelia™ and STRIP™ according to serotype had
been reported in samples from French Guiana [20,24].
Therefore, other reasons such as a decreased avidity of
NS1 tests for certain geographical dengue virus clades,
as proposed before, could be explored [13].
One limitation of the present study was residual mis-
classification of non-dengue cases, which would under-
estimate the specificity of the tests. This is probably low
because most negative (92/98) samples were analyzed by
at least two gold standard methods. Confirmation of
non-dengue diagnosis was not sought due to limited
sample volume. Specificities were relatively high and
similar to previous reports in South America [13].
Further misclassification is likely in secondary and pri-
mary infections as we did not use a gold standard
method such as a quantitative HI due to limited funds
and in some samples not enough available volume. The
use of one of the study tests (SD Bioline™) to define pre-
s e n c eo fb o t hI g Ga n dI g Mw o u l dt e n dt oo v e r e s t i m a t e
the sensitivity of IgM in secondary infections. Neverthe-
less, the findings were consistent with previous reports
of the increased test sensitivity in secondary infections
provided by the addition of IgM to NS1 [6]. Yellow
Fever vaccination (YFV) also is a source of potential
false positives with IgG but this information was not
available for the study samples. YFV is recommended in
Colombia and therefore it is important to include infor-
mation on YFV status of subjects in future studies to
assess the degree of misclassification.
Conclusions
Of the 5 tests assessed, SD Bioline™ NS1/IgM/IgG per-
formed significantly better than the other tests. Therefore,
the simultaneous detection of NS1/IgM/IgG would be
potentially useful to diagnose dengue in both endemic and
non endemic areas. All NS1 tests were highly reproduci-
ble. Clinicians must be aware that a negative result does
not rule out dengue. To take evidence based decisions
about the usefulness of this test in clinical settings, it is
recommended to assess its performance in consecutive
subjects with potential dengue infection under routine
conditions at health centers with different levels of com-
plexity. Further studies are required to assess the potential
impact of implementing early laboratory diagnosis of den-
gue in terms of prognosis and cost-effectiveness. Second-
ary infection, viral serotype and time since fever onset
Table 4 Sensitivity of SD Bioline™ Dengue Duo according to presence of IgG and days of fever.
Component of SD Bioline™
Dengue Duo analyzed
Negative IgG in acute sera Positive IgG in acute sera
Days of fever onset 0 to 3 4 to 7 0 to 3 4 to 7
Dengue samples N = 108 N = 46 N = 14 N = 50
Only NS1 Positive tests 71 30 2 8
Sensitivity % 65.7 65.2 14.3 16
(95% CI) (56-74.6) (49.8-78.6) (1.78-42.8) (7.17-29.1)
Any of NS1/IgM Positive tests 78 34 13 46
Sensitivity % 72.2 74 93 92
(95% CI) (62.8-80.4) (59-85.7) (66.1-99.8) (80.8-97.8)
Any of NS1/IgM/IgG Positive tests 78 34 14 50
Sensitivity % 72.2 74 100 100
(95% CI) (62.8-80.4) (59-85.7) (76.8-100) (92.9-100)
Osorio et al. Virology Journal 2010, 7:361
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Page 8 of 10should be taken into account as sources of heterogeneity
in the interpretation and meta-analysis of NS1-based diag-
nostic tests.
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